This Viewpoint explains how “skinny labeling” works (bioequivalent drugs approved for unpatented uses and excluding patented indications from the generic drug’s labeling), the uncertainty about this pathway, and how the government and generic manufacturers can help restore timely generic competition in the face of brand-name drugs protected by patents.
Source: JAMA Online First